Active — Not RecruitingNot Applicable

Study of Two Different Putty Bone Grafts in Treatment of Intrabony Defects with the Aid of Intramarrow Penetration Technique

Egypt20 participantsStarted 2024-06-01

Plain-language summary

to evaluate and compare efficacy of two different putty forms for both Demineralized Bone Matrix allograft (DBM) and nanocrystalline hydroxyapatite (NCHA) in treatment of intrabony defects with the aid of intramarrow penetration, A total of twenty patients will be diagnosed with stage III grade B periodontitis according to the Caton classification. They will be selected from the clinic of Department of Periodontology and Oral Medicine, Faculty of Dentistry, Mansoura University Patients will be classified into two groups: * Group I: in this group, ten patients with intrabony defect will be treated by open flap debridement with decortication followed by placement of nanocrystalline hydroxyapatite in putty form as grafting material. * Group II: in this group, ten patients with intrabony defect will be treated by open flap debridement with decortication followed by placement of Demineralized Bone Matrix allograft putty as grafting material. Clinical assessment: including the following parameters: 1. Plaque Index (PI). 2. Gingival Index (GI). 3. Clinical Attachment Level (CAL) 4. Probing Depth (PD) Radiological parameters * The height of the defect: Distance from the CEJ to the alveolar crest (AC) * Depth of the defect: Distance from CEJ to the base of the defect * Width of the defect: Highest point of the AC to the root adjacent to the defect * Defect angle: Two lines that represent the root surface of the involved tooth and the bone defect surface

Who can participate

Age range

25 Years – 55 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Both genders with 25-55 years of age. * Patients with intrabony defects in the Stage III Grade B periodontitis. * Individuals with probing depth ≥ 5mm. * Individuals with clinical attachment loss ≥ 5mm. * Presence of at least one or more intrabony defect ≥ 3 mm on the radiographs. * patients who had not periodontal therapy in the previous 6 months. Exclusion Criteria: * Patient with stage I, II and IV periodontitis. * Pregnant or lactating mothers. * Patients having any systemic disease. * allergies to Local anesthesia and chlorhexidine, antibiotics, and analgesics will be excluded.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Clinical (Clinical attachment level CAL)

Timeframe: 3,6,12 months

Radiographical Analysis of bone defect

Timeframe: at baseline, 6, 12 months

Trial details

NCT IDNCT06699043

SponsorAfaf Mansour Dao Abdelslam

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03

View on ClinicalTrials.gov More Intrabony Defects in Chronic Periodontitis trials